比利时PCV13转PCV10后儿童肺炎链球菌携带血清型与耐药随访
比利时在疫苗接种计划由PCV13转为PCV10后开展三年鼻咽携带研究,比较第二年与基线的携带率、血清型分布及抗菌药物敏感性。结果显示携带率仍高,PCV13血清型占比较低但其中3、6A、19A占比显著上升,非敏感率与基线相当。
要点
- PCV13转为PCV10后儿童肺炎链球菌携带率仍高。
- 携带者中PCV13血清型占比较低,但3、6A、19A占比显著上升。
- 至少一种抗生素非敏感率与基线相当。
核心结论
- 比利时完成PCV13转PCV10后,日托中心PCV13血清型携带者中PCV13-non-PCV10血清型(主要为19A)占比显著增加,提示随PCV10接种人群扩大需加强监测。
研究设计与样本
- 研究在比利时开展三年肺炎链球菌携带研究,比较转换疫苗后第二年(2016年10月至2017年6月)与基线(2016年1月至7月)的鼻咽携带、血清型分布及抗菌药物敏感性。
- 对象为6-30月龄儿童,来自112家日托中心或因急性中耳炎就诊于21名医生,采集单次鼻咽拭子进行培养、药敏筛查和血清分型。
- 第二年共收集1218份样本,多数儿童(>85%)按年龄适龄接种,接种PCV13仅、PCV10仅或混合疫苗的比例在日托中心与中耳炎就诊儿童中均有报告。
主要发现
- 第二年肺炎链球菌携带率较高:日托中心68.2%,中耳炎就诊儿童64.8%。
- 携带者中PCV13血清型占比较低:日托中心第二年3.5% vs 第一年5.4%;中耳炎就诊儿童7.6% vs 7.7%。
- PCV13-non-PCV10血清型占比与第一年相比未显著增加:日托中心1.6% vs 0.9%,中耳炎就诊儿童5.1% vs 0.0%。
- 日托中心PCV13血清型携带者中3、6A、19A血清型占比在第二年显著更高(46.2% vs 第一年16.0%,p=0.034)。
- 第二年主要非疫苗血清型为23B和15B;对五种抗生素(青霉素、四环素、红霉素、左氧氟沙星、复方磺胺甲噁唑)中至少一种非敏感率与第一年相当:日托中心41.3% vs 42.4%,中耳炎就诊儿童49.4% vs 48.1%。
临床怎么用
- 在PCV10接种人群中应持续监测肺炎链球菌血清型分布,关注PCV13-non-PCV10血清型(尤其19A)及3、6A、19A的局部变化。
- 儿童肺炎链球菌分离株对青霉素、四环素、红霉素、左氧氟沙星和复方磺胺甲噁唑的非敏感率仍较高,经验性用药需结合当地药敏数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A three year pneumococcal carriage study was set up in Belgium when the vaccination programme switched from a 13-valent (PCV13) to a 10-valent (PCV10) vaccine. We compared the first follow-up period (October 2016 - June 2017, year 2, Y2) for nasopharyngeal carriage, serotype distribution and antimicrobial susceptibility of S. pneumoniae with the baseline (January-July 2016, year 1, Y1). MATERIALS/METHODS: A single nasopharyngeal swab was taken in children (6-30 months), either attending one of the 112 day-care centres (DCCs), or visiting one of the 21 physicians for an acute otitis media (AOM). S. pneumoniae were cultured, screened for antimicrobial susceptibility, and serotyped. RESULTS: In Y2, 1218 samples were collected. The majority of the Y2-children (>85%) was vaccinated appropriately for their age. Children in Y2 received either PCV13 only (DCC: 23.5%; AOM: 24.6%), PCV10 only (DCC: 29.8%; AOM: 37.7%), or a mix of both vaccines (DCC: 31.9%; AOM: 25.4%). Pneumococcal carriage rates were high (Y2, DCC: 68.2%; AOM: 64.8%). Among carriers, prevalence of PCV13 serotypes was low (Y2 vs Y1, DCC: 3.5% vs 5.4%; AOM: 7.6% vs 7.7%). Although prevalence of PCV13-non-PCV10 serotypes did not increase significantly compared to Y1 (Y2 vs Y1, DCC: 1.6% vs 0.9%; Y2 vs Y1, AOM: 5.1% vs 0.0%), the proportion of serotypes 3, 6A, 19A among PCV13 serotype carriers in DCC was significantly higher in Y2 (46.2% vs Y1: 16.0%, p-value = 0.034). Serotypes 23B and 15B were the predominant non-vaccine serotypes (Y2). Among detected strains, non-susceptibility to at least one of five antibiotics tested (penicillin, tetracycline, erythromycin, levofloxacin, cotrimoxazole) was comparable to Y1 (Y2 vs Y1, DCC: 41.3% vs 42.4%; AOM: 49.4% vs 48.1%). CONCLUSION: After completion of the PCV13-to-PCV10 vaccine switch in Belgium, the proportion of PCV13-non-PCV10 serotypes (mainly 19A) significantly increased among PCV13 serotype carriers in DCC, stressing the need for strengthened surveillance as the PCV10-vaccinated population grows.
引用
- Wouters I, Desmet S, Van Heirstraeten L, et al. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium. Vaccine. 2019. PMID: 30665775. doi:10.1016/j.vaccine.2018.12.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。